{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:47:20Z","timestamp":1768398440063,"version":"3.49.0"},"reference-count":18,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation, Regional Science Foundation Project","award":["82160343"],"award-info":[{"award-number":["82160343"]}]},{"name":"Joint Program of Applied Basic Research of Yunnan Provincial Department of Science and Technology-Kunming Medical University","award":["202301AY070001-106"],"award-info":[{"award-number":["202301AY070001-106"]}]},{"name":"\u201cFamous Doctor\u201d Special Project of Ten Thousand People Plan of Yunnan Province","award":["YNWR-MY-2020-095"],"award-info":[{"award-number":["YNWR-MY-2020-095"]}]},{"DOI":"10.13039\/501100019413","name":"Yunnan Provincial Department of Education Science Research Fund Project","doi-asserted-by":"crossref","award":["2024J0246"],"award-info":[{"award-number":["2024J0246"]}],"id":[{"id":"10.13039\/501100019413","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Medical Leading Talents Training Program of Yunnan Provincial Health Commission","award":["L-2019028"],"award-info":[{"award-number":["L-2019028"]}]},{"name":"Key Project of the Joint Special Program of Kunming Medical University","award":["202401AB070049"],"award-info":[{"award-number":["202401AB070049"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lung adenocarcinoma is a prevalent malignancy. Mutations in the epidermal growth factor receptor (EGFR) have introduced novel prospects for targeted therapies. However, the status of EGFR mutations alone may be insufficient to fully predict treatment outcomes. To this end, the present research was performed to evaluate the serum markers associated with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with lung adenocarcinoma and bone metastases, specifically focusing on the prognostic value of EGFR-TKI therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 164 patients diagnosed with lung adenocarcinoma and bone metastases at Yunnan Cancer Hospital between January 2019 and December 2020. Clinical and follow-up data were collected, and a Cox regression model was employed to evaluate the combined predictive value of serum markers for survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The findings revealed that variables identified through Cox regression analysis included age, the neutrophil-to-lymphocyte ratio (NLR), carcinoembryonic antigen (CEA), and Cytokeratin 19 fragment (Cyfra21-1), all exhibiting significance levels of\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05. The Cox model exhibited a c-index of 0.644, and the calibration curve demonstrated satisfactory performance, indicating the moderate predictive capacity of the model. A nomogram was subsequently constructed to visualize these results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This research successfully developed a nomogram based on the Cox regression model to predict prognosis and treatment outcomes in patients with lung adenocarcinoma and bone metastases undergoing EGFR-TKI therapy. This facilitates the avoidance of poor treatment outcomes by enabling individualized therapeutic approaches, thereby simplifying the development of the most appropriate treatment plans and ultimately improving patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20537","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:30:23Z","timestamp":1768379423000},"page":"e20537","source":"Crossref","is-referenced-by-count":0,"title":["Serum markers for prognostic value of EGFR-TKI in lung adenocarcinoma with bone metastases: a retrospective study"],"prefix":"10.7717","volume":"14","author":[{"given":"Jiali","family":"Li","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Puer People\u2019s Hospital, Puer, Yunnan, China"},{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuting","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery,The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlei","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqiu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming Medical College, Kunming, Yunnan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"12","key":"10.7717\/peerj.20537\/ref-1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1159\/000492344","article-title":"Neutrophil to lymphocyte ratio as a prognostic factor in European patients with epidermal growth factor receptor-mutant non-small cell lung cancer treated with tyrosine kinase inhibitors","volume":"41","author":"Aguiar-Bujanda","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.7717\/peerj.20537\/ref-2","doi-asserted-by":"publisher","first-page":"692788","DOI":"10.3389\/fonc.2021.692788","article-title":"Predictive and prognostic biomarkers for lung cancer bone metastases and their therapeutic value","volume":"11","author":"Chai","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.20537\/ref-3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/OTT.S407301","article-title":"The role of neutrophil-to-lymphocyte ratio in advanced EGFR-mutant NSCLC patients treated with first-line osimertinib","volume":"16","author":"Chen","year":"2023","journal-title":"OncoTargets and Therapy"},{"issue":"3","key":"10.7717\/peerj.20537\/ref-4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.7717\/peerj.20537\/ref-5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.20537\/ref-6","first-page":"3205","article-title":"Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib","volume":"34","author":"Fiala","year":"2014","journal-title":"Anticancer Research"},{"issue":"1","key":"10.7717\/peerj.20537\/ref-7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12885-022-09741-8","article-title":"Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastases","volume":"22","author":"Gen","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.7717\/peerj.20537\/ref-8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/cancers12010233","article-title":"Elevated expression of lumican in lung cancer cells promotes bone metastases through an autocrine regulatory mechanism","volume":"12","author":"Hsiao","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.7717\/peerj.20537\/ref-9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s12885-023-10767-9","article-title":"Prognostic value of CYFRA 21\u22121 and Ki67 in advanced NSCLC patients with wild-type EGFR","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.7717\/peerj.20537\/ref-10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jtho.2015.12.103","article-title":"Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs","volume":"11","author":"Lin","year":"2015","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"11","key":"10.7717\/peerj.20537\/ref-11","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jtho.2018.07.096","article-title":"An integrative analysis of transcriptome and epigenome features of ASCL1-positive lung adenocarcinomas","volume":"13","author":"Miyashita","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.7717\/peerj.20537\/ref-12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.4103\/jcrt.JCRT_1762_20","article-title":"Prognostic value of diffuse cancer inflammation index (ALI), serum neutrophil\/lymphocyte (NLR) and platelet\/lymphocyte (PLR) in advanced-stage lung cancer","volume":"20","author":"Ozturk","year":"2024","journal-title":"Journal of Cancer Research and Therapeutics"},{"issue":"5","key":"10.7717\/peerj.20537\/ref-13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2217\/fon-2018-0613","article-title":"Bone metastases and skeletal-related events: incidence and prognosis according to histological subtype of lung cancer","volume":"15","author":"Silva","year":"2019","journal-title":"Future Oncology"},{"issue":"3","key":"10.7717\/peerj.20537\/ref-14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"1","key":"10.7717\/peerj.20537\/ref-15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1186\/s12885-020-07046-2","article-title":"Establishment of a serological molecular model for the early diagnosis and progression monitoring of bone metastases in lung cancer","volume":"20","author":"Teng","year":"2020","journal-title":"BMC Cancer"},{"issue":"9","key":"10.7717\/peerj.20537\/ref-16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/1759-7714.14808","article-title":"Serum cross-linked N-telopeptide of type I collagen as a potential diagnostic marker for bone metastases in lung cancer: an updated meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Thoracic Cancer"},{"issue":"10","key":"10.7717\/peerj.20537\/ref-17","doi-asserted-by":"publisher","first-page":"e069908","DOI":"10.1136\/bmjopen-2022-069908","article-title":"Prevalence and prognosis of bone metastases in common solid cancers at initial diagnosis: a population-based study","volume":"13","author":"Zhang","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"10.7717\/peerj.20537\/ref-18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12957-021-02141-5","article-title":"Establishment of a regression model of bone metabolism markers for the diagnosis of bone metastases in lung cancer","volume":"19","author":"Zhu","year":"2021","journal-title":"World Journal of Surgical Oncology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20537.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20537.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20537.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20537.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T08:30:28Z","timestamp":1768379428000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":18,"alternative-id":["10.7717\/peerj.20537"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20537","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"e20537"}}